BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
Number Citing Articles
1 McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard LP, Grewal K, Lapeyraque AL, Patriquin CJ, Pavenski K, Licht C. Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review. Can J Kidney Health Dis 2021;8:20543581211008707. [PMID: 33996107 DOI: 10.1177/20543581211008707] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Cheung V, Trachtman H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) 2014;1:42. [PMID: 25593915 DOI: 10.3389/fmed.2014.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
4 Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem 2012;287:13829-39. [PMID: 22393049 DOI: 10.1074/jbc.M112.344325] [Cited by in Crossref: 91] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
5 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
6 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Rawson NSB. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access? J Popul Ther Clin Pharmacol 2020;27:e48-64. [PMID: 32124580 DOI: 10.15586/jptcp.v27i1.658] [Reference Citation Analysis]
8 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
9 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
10 Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-45. [PMID: 23787556 DOI: 10.1093/ndt/gft198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
11 Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One 2015;10:e0124655. [PMID: 25951460 DOI: 10.1371/journal.pone.0124655] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
12 Gosain R, Gill A, Fuqua J, Volz LH, Kessans Knable MR, Bycroft R, Seger S, Gosain R, Rios JA, Chao JH. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep 2017;5:1926-30. [PMID: 29225827 DOI: 10.1002/ccr3.1214] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
13 Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Am J Case Rep 2019;20:1460-5. [PMID: 31582717 DOI: 10.12659/AJCR.916994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Vinturache A, Popoola J, Watt-Coote I. The Changing Landscape of Acute Kidney Injury in Pregnancy from an Obstetrics Perspective. J Clin Med 2019;8:E1396. [PMID: 31500091 DOI: 10.3390/jcm8091396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28:827-30. [PMID: 23389237 DOI: 10.1007/s00467-013-2416-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
16 Ersoy Dursun F, Yesil G, Sasak G, Dursin H. Familial Atypical Hemolytic Uremic Syndrome with Positive p.S1191L (c.3572C>T) Mutation on the CFH Gene: A Single-center Experience. Balkan J Med Genet 2021;24:81-8. [PMID: 34447663 DOI: 10.2478/bjmg-2021-0007] [Reference Citation Analysis]
17 Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfusion and Apheresis Science 2016;55:357-62. [DOI: 10.1016/j.transci.2016.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology 2016;221:1110-23. [PMID: 27297292 DOI: 10.1016/j.imbio.2016.05.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
19 Risitano AM. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 2012;217:1080-7. [PMID: 22964233 DOI: 10.1016/j.imbio.2012.07.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
20 Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant 2018;33:635-45. [PMID: 29106598 DOI: 10.1093/ndt/gfx196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
21 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
22 Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016;8:6625. [PMID: 27781079 DOI: 10.4081/hr.2016.6625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
23 Rawal S, Einbinder Y, Rubin L, Perl J, Trinkaus M, Teitel J, Pavenski K. Thrombotic microangiopathy in a patient with adult-onset Still's disease. Transfusion 2014;54:2983-7. [PMID: 24845532 DOI: 10.1111/trf.12708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Risitano AM. Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America 2015;29:561-82. [DOI: 10.1016/j.hoc.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
25 Penchev V, Boueva A, Kamenarova K, Roussinov D, Tzveova R, Ivanova M, Dimitrova V, Kremensky I, Mitev V, Kaneva R, Beltcheva O. A familial case of severe infantile nephronophthisis explained by oligogenic inheritance. Eur J Med Genet 2017;60:321-5. [PMID: 28392475 DOI: 10.1016/j.ejmg.2017.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
26 Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, Storm M, Wijnsma KL, Gelens M, van de Kar NCAJ, Wetzels J, Dirksen CD. Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient 2017;10:629-42. [PMID: 28357591 DOI: 10.1007/s40271-017-0234-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
27 Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018;3:99128. [PMID: 29563339 DOI: 10.1172/jci.insight.99128] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
28 Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann R, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clin Pharmacol Ther 2017;102:671-8. [DOI: 10.1002/cpt.686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
29 Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531-536. [PMID: 23542698 DOI: 10.1038/ng.2590] [Cited by in Crossref: 317] [Cited by in F6Publishing: 261] [Article Influence: 35.2] [Reference Citation Analysis]
30 Blasco Pelicano M, Rodríguez de Córdoba S, Campistol Plana JM. Síndrome hemolítico urémico atípico. Medicina Clínica 2015;145:438-45. [DOI: 10.1016/j.medcli.2014.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Fayek SA, Allam SR, Martinez E, Pan G, Dao A, Rofaiel G. Atypical Hemolytic Uremic Syndrome After Kidney Transplantation: Lessons Learned From the Good, the Bad, and the Ugly. A Case Series With Literature Review. Transplant Proc 2020;52:146-52. [PMID: 31924403 DOI: 10.1016/j.transproceed.2019.10.015] [Reference Citation Analysis]
32 Ali MN, Syed A, Bhandari S. Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. Transplant Proc 2013;45:3284-8. [PMID: 24182801 DOI: 10.1016/j.transproceed.2013.07.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, Edefonti A. Skin Involvement in Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases 2014;63:652-5. [DOI: 10.1053/j.ajkd.2013.09.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
34 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
35 Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A. Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:2215-20. [DOI: 10.1007/s00467-015-3189-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
36 Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K. Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary? BMC Nephrol 2018;19:365. [PMID: 30558570 DOI: 10.1186/s12882-018-1168-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 2018;22:653-60. [PMID: 28939980 DOI: 10.1007/s10157-017-1478-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Brocklebank V, Kavanagh D. Protecting the kidney from complement: atypical haemolytic uraemic syndrome. Clin Med (Lond) 2014;14 Suppl 6:s89-94. [PMID: 25468928 DOI: 10.7861/clinmedicine.14-6-s89] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
40 Mukherjee AA, Kandhare AD, Bodhankar SL. Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO. Ren Fail 2018;40:107-18. [PMID: 29363392 DOI: 10.1080/0886022X.2018.1427110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E. [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics]. Rev Med Interne 2017;38:817-24. [PMID: 28711159 DOI: 10.1016/j.revmed.2017.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society: aHUS diagnostic guidelines. Pediatr Int 2014;56:1-5. [DOI: 10.1111/ped.12274] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
43 Smirnova TV, Kozlovskaya NL, Sheludchenko VM. [Ocular manifestations of primary thrombotic microangiopathy]. Vestn Oftalmol 2021;137:138-44. [PMID: 34726868 DOI: 10.17116/oftalma2021137051138] [Reference Citation Analysis]
44 Raina R, Chauvin A, Fox K, Kesav N, Ascha M, Vachharajani TJ, Krishnappa V. Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients. Ann Transplant 2018;23:631-8. [PMID: 30190449 DOI: 10.12659/AOT.909781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Michelfelder S, Parsons J, Bohlender LL, Hoernstein SNW, Niederkrüger H, Busch A, Krieghoff N, Koch J, Fode B, Schaaf A, Frischmuth T, Pohl M, Zipfel PF, Reski R, Decker EL, Häffner K. Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders. J Am Soc Nephrol 2017;28:1462-74. [PMID: 27932477 DOI: 10.1681/ASN.2015070745] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
46 Brocklebank V, Wong EK, Fielding R, Goodship TH, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri.. Clin Kidney J 2014;7:286-8. [PMID: 24944786 DOI: 10.1093/ckj/sfu032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
47 Janssen van Doorn K, Dirinck E, Verpooten GA, Couttenye MM. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J 2013;6:216-9. [PMID: 25006455 DOI: 10.1093/ckj/sfs190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
48 Nilsson OR, Lannergård J, Morgan BP, Lindahl G, Gustafsson MC. Affinity purification of human factor H on polypeptides derived from streptococcal m protein: enrichment of the Y402 variant. PLoS One 2013;8:e81303. [PMID: 24278416 DOI: 10.1371/journal.pone.0081303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, Smith RJ, Afshar-Kharghan V. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122:1487-1493. [PMID: 23847193 DOI: 10.1182/blood-2013-03-492421] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
50 Williams LA, Marques MB; for the Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). Am J Clin Pathol 2016;145:158-65. [DOI: 10.1093/ajcp/aqv086] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
51 Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013;64:307-24. [PMID: 23121180 DOI: 10.1146/annurev-med-072211-110606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
52 Terano C, Ishikura K, Hamada R, Yoshida Y, Kubota W, Okuda Y, Shinozuka S, Harada R, Iyoda S, Fujimura Y, Hamasaki Y, Hataya H, Honda M. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients. Nephrology (Carlton) 2018;23:539-45. [PMID: 28387984 DOI: 10.1111/nep.13054] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
53 Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 2013;81:400-3. [PMID: 23786906 DOI: 10.1016/j.mehy.2013.05.030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
54 Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab: An infant with eculizumab-resistant aHUS. Nephrology 2016;21:261-5. [DOI: 10.1111/nep.12582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sinibaldi S, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. Pediatr Transplant. 2013;17:E177-E181. [PMID: 24118826 DOI: 10.1111/petr.12151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
56 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
57 Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y. La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques. La Revue de Médecine Interne 2015;36:328-38. [DOI: 10.1016/j.revmed.2014.10.364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
59 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
60 Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, Coucelo M, Manco L, Maia T, Mendes MJ, Del Orbe Barreto R, Corrales I, Vidal F, Ribeiro ML. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1:69-80. [PMID: 30046676 DOI: 10.1002/rth2.12016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
61 Loirat C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr 2013;25:216-24. [PMID: 23422353 DOI: 10.1097/MOP.0b013e32835e7888] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
62 Bekassy ZD, Kristoffersson A, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, Hue C, Fremeaux-bacchi V, Karpman D. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation 2013;28:2899-907. [DOI: 10.1093/ndt/gft340] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
63 Emirova K, Volokhina E, Tolstova E, van den Heuvel B. Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep 2016;2016:bcr2015213928. [PMID: 26880823 DOI: 10.1136/bcr-2015-213928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
64 Thajudeen B, Sussman A, Bracamonte E. A case of atypical hemolytic uremic syndrome successfully treated with eculizumab. Case Rep Nephrol Urol 2013;3:139-46. [PMID: 24570684 DOI: 10.1159/000357520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
65 Noronha N, Costa FD, Dias A, Dinis A. Complement factor B mutation-associated aHUS and myocardial infarction. BMJ Case Rep 2017;2017:bcr-2017-219716. [PMID: 28710236 DOI: 10.1136/bcr-2017-219716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C, López Andrade B, Lumbreras J, Obrador Mulet A, Perez Montaña A, Ferreruela Serlavos M, Ayestarán Rota JI, Ferrer Balaguer J, Delgado Sanchez O, Pallares Ferreres L, Mas Bonet A, Picado Valles MJ, de Gopegui Valero RMR. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One 2018;13:e0206558. [PMID: 30388144 DOI: 10.1371/journal.pone.0206558] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
67 Liszewski MK, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics 2015;9:7. [PMID: 26054645 DOI: 10.1186/s40246-015-0029-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
68 Chua J, Paizis K, He SZ, Mount P. Suspected atypical haemolytic uraemic syndrome in two post-partum patients with foetal-death in utero responding to eculizumab: Response to eculizumab in aHUS post FDIU. Nephrology 2017;22:18-22. [DOI: 10.1111/nep.12935] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
69 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
70 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
71 Loirat C, Mariani-Kurkdjian P, Fremeaux-Bacchi V. [Hemolytic uremic syndrome as of 2013]. Arch Pediatr 2013;20:827-30. [PMID: 23835098 DOI: 10.1016/j.arcped.2013.05.015] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Dutra FF, Bozza MT. Heme on innate immunity and inflammation. Front Pharmacol 2014;5:115. [PMID: 24904418 DOI: 10.3389/fphar.2014.00115] [Cited by in Crossref: 172] [Cited by in F6Publishing: 157] [Article Influence: 21.5] [Reference Citation Analysis]
73 Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) 2012;4:1261-87. [PMID: 23202315 DOI: 10.3390/toxins4111261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
74 Asif A, Haqqie SS, Ghate K, Mathew RO, Vachharajani T, Nayer A. Continued Eculizumab Therapy for Persistent Atypical Hemolytic Uremic Syndrome. TOUNJ 2013;6:46-8. [DOI: 10.2174/1874303x01306010046] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
75 Kimman ML, Wijsenbeek MS, van Kuijk SMJ, Wijnsma KL, van de Kar NCAJ, Storm M, van Jaarsveld X, Dirksen CD; PESaM Collaborating Group. Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient 2019;12:149-62. [PMID: 30367435 DOI: 10.1007/s40271-018-0340-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
76 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
77 Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. [PMID: 25250305 DOI: 10.3389/fped.2014.00097] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
78 Åkesson A, Blom AM, Klintman J, Zetterberg E. Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012. Nephrology (Carlton) 2017;22:555-61. [PMID: 27175932 DOI: 10.1111/nep.12818] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int 2019;96:67-79. [PMID: 30910380 DOI: 10.1016/j.kint.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
80 Riedl M, Hofer J, Giner T, Rosales A, Häffner K, Simonetti GD, Walden U, Maier T, Heininger D, Jeller V, Weiss G, van den Heuvel L, Zimmerhackl LB, Würzner R, Jungraithmayr TC. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods 2016;435:60-7. [PMID: 27238216 DOI: 10.1016/j.jim.2016.05.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 Wortmann SB, Espeel M, Almeida L, Reimer A, Bosboom D, Roels F, de Brouwer AP, Wevers RA. Inborn errors of metabolism in the biosynthesis and remodelling of phospholipids. J Inherit Metab Dis 2015;38:99-110. [DOI: 10.1007/s10545-014-9759-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
82 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
83 Regal JF, Gilbert JS, Burwick RM. The complement system and adverse pregnancy outcomes. Mol Immunol 2015;67:56-70. [PMID: 25802092 DOI: 10.1016/j.molimm.2015.02.030] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 11.9] [Reference Citation Analysis]
84 Stritt A, Tschumi S, Kottanattu L, Bucher BS, Steinmann M, von Steiger N, Stephan R, Hachler H, Simonetti GD. Neonatal Hemolytic Uremic Syndrome After Mother-to-Child Transmission of a Low-Pathogenic stx2b Harboring Shiga Toxin-Producing Escherichia coli. Clinical Infectious Diseases 2012;56:114-6. [DOI: 10.1093/cid/cis851] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
85 Tanriover B, Lakhia R, Shen YM, Sandikci B, Saxena R, MacConmara M, Soyombo AA, Rajora N, Hardy MA. Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States. Transplant Direct 2015;1:e41. [PMID: 26949736 DOI: 10.1097/TXD.0000000000000555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
86 Nerrant E, Charif M, Ramay AS, Perrochia H, Patrier L, de Champfleur NM, Renard D, Labauge P. Hemolytic uremic syndrome: an unusual complication of interferon-β treatment in a MS patient. J Neurol 2013;260:1915-6. [PMID: 23708674 DOI: 10.1007/s00415-013-6961-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
87 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
88 Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol 2013;28:675-7. [PMID: 23389238 DOI: 10.1007/s00467-013-2423-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
89 Weil EL, Rabinstein AA. Neurological manifestations of thrombotic microangiopathy syndromes in adult patients. J Thromb Thrombolysis 2021;51:1163-9. [PMID: 33755882 DOI: 10.1007/s11239-021-02431-5] [Reference Citation Analysis]
90 Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, Seppänen MRJ, Sullivan KE, Jolles S. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. J Clin Immunol 2020;40:576-91. [PMID: 32064578 DOI: 10.1007/s10875-020-00754-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
91 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
92 Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017;2017:bcr-2016-219065. [PMID: 28446488 DOI: 10.1136/bcr-2016-219065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
93 Novikov P, Kozlovskaya N, Moiseev S, Shilov E, Bobkova I, Schreiber A, Tsvetkov D, Gollasch M, Mah N, El Amrani K, Kurtz A. Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy. Biomed Hub 2016;1:1-11. [PMID: 31988889 DOI: 10.1159/000453106] [Reference Citation Analysis]
94 Yüksel S, Evrengül H, Özçakar ZB, Becerir T, Yalçın N, Korkmaz E, Ozaltin F. First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients. Pediatr Drugs 2016;18:413-20. [DOI: 10.1007/s40272-016-0194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
95 Mallett A, Hughes P, Szer J, Tuckfield A, Van Eps C, Cambell SB, Hawley C, Burke J, Kausman J, Hewitt I, Parnham A, Ford S, Isbel N. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort: Eculizumab treatment of aHUS in Australia. Intern Med J 2015;45:1054-65. [DOI: 10.1111/imj.12864] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
96 Piedrafita A, Ribes D, Cointault O, Chauveau D, Faguer S, Huart A. Plasma exchange and thrombotic microangiopathies: From pathophysiology to clinical practice. Transfus Apher Sci 2020;59:102990. [PMID: 33272850 DOI: 10.1016/j.transci.2020.102990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra MK, Ilyas SH, Al-Khasawneh E. Eculizumab in paediatric atypical haemolytic uraemic syndrome: Lessons learned from a single-centre experience in the United Arab Emirates. J Paediatr Child Health 2019;55:1237-40. [PMID: 30714243 DOI: 10.1111/jpc.14390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
98 Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019;12:333-7. [PMID: 31198225 DOI: 10.1093/ckj/sfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
99 Wijnsma KL, van Bommel SA, van der Velden T, Volokhina E, Schreuder MF, van den Heuvel LP, van de Kar NC. Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatr Nephrol 2016;31:2163-70. [PMID: 27240858 DOI: 10.1007/s00467-016-3420-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
100 Chen Q, Bao H, Wu H, Zhao S, Huang S, Zhao F. Diagnosis of cobalamin C deficiency with renal abnormality from onset in a Chinese child by next generation sequencing: A case report. Exp Ther Med 2017;14:3637-43. [PMID: 29042959 DOI: 10.3892/etm.2017.4970] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
101 Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2018;65:509-25. [DOI: 10.1016/j.pcl.2018.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
102 Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE. Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Medicine (Baltimore) 2016;95:e5007. [PMID: 27684863 DOI: 10.1097/MD.0000000000005007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
103 Ávila A, Gavela E, Sancho A. Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity. Front Med (Lausanne) 2021;8:642864. [PMID: 33898482 DOI: 10.3389/fmed.2021.642864] [Reference Citation Analysis]
104 Çakar N, Ozcakar Z, Ozaltin F, Koyun M, Celikel acar B, Bahat E, Gulhan B, Korkmaz E, Yurt A, Yılmaz S, Soylemezoglu O, Yalcinkaya F. Atypical Hemolytic Uremic Syndrome in Children Aged <2 Years. Nephron 2018;139:211-8. [DOI: 10.1159/000487609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
105 Cabarcas-Barbosa O, Aroca-Martínez G, Musso CG, Ramos-Bolaños E, González-Tórres H, Espitaleta-Vergara Z, Domínguez-Vargas A, Ararat-Rodriguez E, Orozco J, Castillo-Parodi L, Conde-Manotas J, Daza-Arnedo R, Rodríguez-SanJuan V, Gómez-Navarro L, Acosta-Madiedo R, Barros-Camargo L, Aduen-Carrillo A, Ayola-Anaya F, Pulgar-Emiliani M, Cadena-Bonfanti A. Atypical hemolytic uremic syndrome in the Colombian Caribbean: its particular characteristics. Int Urol Nephrol 2021. [PMID: 34643860 DOI: 10.1007/s11255-021-03011-5] [Reference Citation Analysis]
106 Zhang Y, Keenan A, Dai DF, May KS, Anderson EE, Lindorfer MA, Henrich JB, Pitcher GR, Taylor RP, Smith RJ. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice. JCI Insight 2020;5:135758. [PMID: 32376801 DOI: 10.1172/jci.insight.135758] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Molecular Immunology 2014;61:110-7. [DOI: 10.1016/j.molimm.2014.06.030] [Cited by in Crossref: 115] [Cited by in F6Publishing: 91] [Article Influence: 14.4] [Reference Citation Analysis]
108 Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J 2013;6:421-5. [PMID: 24422172 DOI: 10.1093/ckj/sft065] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
109 Briones MA. Hemolytic Uremic Syndrome. Transfusion Medicine and Hemostasis. Elsevier; 2013. pp. 669-74. [DOI: 10.1016/b978-0-12-397164-7.00102-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Bruneau S, Néel M, Roumenina LT, Frimat M, Laurent L, Frémeaux-Bacchi V, Fakhouri F. Loss of DGKε induces endothelial cell activation and death independently of complement activation. Blood 2015;125:1038-46. [PMID: 25498910 DOI: 10.1182/blood-2014-06-579953] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
111 Condom P, Mansuy JM, Decramer S, Izopet J, Mengelle C. Atypical hemolytic uremic syndrome triggered by varicella infection. IDCases 2017;9:89-90. [PMID: 28725563 DOI: 10.1016/j.idcr.2017.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
112 Zhou D, Tan Y, Liu X, Tang L, Wang H, Shen J, Wang W, Zhuang L, Tao J, Su J, Gong T, Liu X, Liang P, Yu F, Zhao M. Patient-specific iPSC-derived endothelial cells reveal aberrant p38 MAPK signaling in atypical hemolytic uremic syndrome. Stem Cell Reports 2021:S2213-6711(21)00377-5. [PMID: 34388364 DOI: 10.1016/j.stemcr.2021.07.011] [Reference Citation Analysis]
113 Hyvärinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood 2016;127:2701-10. [PMID: 27006390 DOI: 10.1182/blood-2015-11-680009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
114 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
115 Mathur P, Hollowoa B, Lala N, Thanendrarajan S, Matin A, Kothari A, Schinke C. Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant. Hematol Rep 2017;9:7094. [PMID: 29071054 DOI: 10.4081/hr.2017.7094] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181:306-13. [PMID: 25079699 DOI: 10.1111/cei.12426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
117 Mizuno M, Ito Y, Morgan BP. Exploiting the nephrotoxic effects of venom from the sea anemone, Phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Mar Drugs 2012;10:1582-604. [PMID: 22851928 DOI: 10.3390/md10071582] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
118 Urban A, Volokhina E, Felberg A, Stasiłojć G, Blom AM, Jongerius I, van den Heuvel L, Thiel M, Ołdziej S, Arjona E, de Córdoba SR, Okrój M. Gain-of-function mutation in complement C2 protein identified in a patient with aHUS. J Allergy Clin Immunol 2020;146:916-919.e11. [PMID: 32113979 DOI: 10.1016/j.jaci.2020.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Medeni SS, Namdaroglu S, Cetintepe T, Ozlu C, Tasli F, Adibelli ZH, Bilgir O, Tatar E. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematol Rep 2018;10:7553. [PMID: 30344987 DOI: 10.4081/hr.2018.7553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
121 Choo SZ, Brown F. Subclinical atypical haemolytic uremic syndrome relapse following discontinuation of eculizumab: aHUS relapse post eculizumab cessation. Nephrology 2017;22:4-6. [DOI: 10.1111/nep.12931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
123 Salameh H, Abu Omar M, Alhariri A, Kisra S, Qasem A, Abdulhak AB. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. Am J Ther 2016;23:e1110-5. [PMID: 25486517 DOI: 10.1097/MJT.0000000000000133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Gilbert RD, Fowler DJ, Angus E, Hardy SA, Stanley L, Goodship TH. Eculizumab therapy for atypical haemolytic uraemic syndrome due to a gain-of-function mutation of complement factor B. Pediatr Nephrol 2013;28:1315-8. [DOI: 10.1007/s00467-013-2492-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
125 Eyler SJ, Meyer NC, Zhang Y, Xiao X, Nester CM, Smith RJ. A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome. Pediatr Nephrol 2013;28:2221-5. [PMID: 23880784 DOI: 10.1007/s00467-013-2560-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
126 Wen J, Wang W, Xu F, Sun J, Chen J, Ni X. C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report. BMC Nephrol 2018;19:148. [PMID: 29940891 DOI: 10.1186/s12882-018-0952-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
127 Turner NA, Moake J. Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis. PLoS One 2013;8:e59372. [PMID: 23555663 DOI: 10.1371/journal.pone.0059372] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
128 Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30:127-34. [PMID: 26995002 DOI: 10.1007/s40620-016-0288-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
129 Bu F, Borsa N, Gianluigi A, Smith RJ. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol 2012;2012:370426. [PMID: 23251215 DOI: 10.1155/2012/370426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
130 Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 2012;27:2323-6. [PMID: 22890512 DOI: 10.1007/s00467-012-2276-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
131 Smith JL, Gunther NW. Commentary: Campylobacter and Hemolytic Uremic Syndrome. Foodborne Pathog Dis 2019;16:90-3. [PMID: 30307748 DOI: 10.1089/fpd.2018.2513] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Ueda Y, Mohammed I, Song D, Gullipalli D, Zhou L, Sato S, Wang Y, Gupta S, Cheng Z, Wang H, Bao J, Mao Y, Brass L, Zheng XL, Miwa T, Palmer M, Dunaief J, Song WC. Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation. Blood 2017;129:1184-96. [PMID: 28057640 DOI: 10.1182/blood-2016-07-728253] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
133 Kopp A, Hebecker M, Svobodová E, Józsi M. Factor h: a complement regulator in health and disease, and a mediator of cellular interactions. Biomolecules 2012;2:46-75. [PMID: 24970127 DOI: 10.3390/biom2010046] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 7.2] [Reference Citation Analysis]
134 Nguyen C, Shapiro R. New immunosuppressive agents in pediatric transplantation. Clinics (Sao Paulo) 2014;69 Suppl 1:8-16. [PMID: 24860853 DOI: 10.6061/clinics/2014(sup01)03] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Dolcemascolo V, Vivarelli M, Colucci M, Diomedi-Camassei F, Piras R, Alberti M, Emma F. Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome. Case Rep Nephrol Dial 2016;6:120-7. [PMID: 27904864 DOI: 10.1159/000449423] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Defendi F, Thielens NM, Clavarino G, Cesbron JY, Dumestre-Pérard C. The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease. Clin Rev Allergy Immunol 2020;58:229-51. [PMID: 31834594 DOI: 10.1007/s12016-019-08774-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
137 Biswas A, Ataya A, Salgado JC, Chandrasekharan S, Machuca TN, Emtiazjoo AM. A 42-Year-Old Woman With Anemia, Shock, and Ischemic Stroke After Lung Transplantation. Chest 2017;151:e63-8. [PMID: 28279287 DOI: 10.1016/j.chest.2016.09.006] [Reference Citation Analysis]
138 Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015;67:276-86. [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
139 Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
140 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
141 Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc 2018;93:1351-62. [PMID: 30286829 DOI: 10.1016/j.mayocp.2018.07.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
142 Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-48. [PMID: 30109445 DOI: 10.1007/s00467-018-4039-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
143 Li J, Song Y, Zhang Y, Li H, Tian M, Li D, Zhang S, Cao G, Liu C. A novel compound heterozygous mutation in DGKE in a Chinese patient causes atypical hemolytic uremic syndrome. Hematology 2020;25:101-7. [PMID: 32091318 DOI: 10.1080/16078454.2020.1731969] [Reference Citation Analysis]
144 Aigner C, Gaggl M, Kain R, Prohászka Z, Garam N, Csuka D, Sunder-Plassmann R, Piggott LC, Haninger-Vacariu N, Schmidt A, Sunder-Plassmann G. Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy. J Clin Med 2020;9:E964. [PMID: 32244370 DOI: 10.3390/jcm9040964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Szarvas N, Szilágyi Á, Tasic V, Nushi-Stavileci V, Sofijanova A, Gucev Z, Szabó M, Szabó A, Szeifert L, Reusz G, Rusai K, Arbeiter K, Müller T, Prohászka Z. First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis. Ital J Pediatr 2014;40:101. [PMID: 25496981 DOI: 10.1186/s13052-014-0101-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
146 Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens 2019;28:278-87. [PMID: 30865166 DOI: 10.1097/MNH.0000000000000499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
147 Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res 2019;54:218-28. [PMID: 31730685 DOI: 10.5045/br.2019.54.3.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
148 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 2015;35:421-47. [PMID: 26456110 DOI: 10.1016/j.nefro.2015.07.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 63] [Article Influence: 12.6] [Reference Citation Analysis]
149 Asif A, Vachharajani T, Salman L, Nayer A. A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implications. TOUNJ 2014;7:91-4. [DOI: 10.2174/1874303x01407010091] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
150 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
151 Jin A, Boroujerdi-Rad L, Shah G, Chen JL. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-9. [PMID: 27478600 DOI: 10.1093/ckj/sfw035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
152 Govindarajan S, Rawat A, Ramachandran R, Hans R, Dawman L, Tiewsoh K. Anti-complement factor I antibody associated atypical hemolytic uremic syndrome - A new insight for future perspective! Immunobiology 2020;225:152000. [PMID: 32962820 DOI: 10.1016/j.imbio.2020.152000] [Reference Citation Analysis]
153 Kobbe R, Schild R, Christner M, Oh J, Loos S, Kemper MJ. Case report - atypical hemolytic uremic syndrome triggered by influenza B. BMC Nephrol 2017;18:96. [PMID: 28320387 DOI: 10.1186/s12882-017-0512-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
154 Vidal E, Garzotto F, Parolin M, Manenti C, Zanin A, Bellettato M, Remuzzi G, Goldstein SL, Murer L, Ronco C. Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purif 2017;44:100-5. [DOI: 10.1159/000470827] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
155 Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis 2017;75. [PMID: 28460033 DOI: 10.1093/femspd/ftx049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
156 Soudabeh H, Ebrahim K, Nakisa H, Akbar D, Rozita HS, Bamedi T. Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome. Cent Eur J Immunol 2014;39:67-70. [PMID: 26155102 DOI: 10.5114/ceji.2014.42127] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 DeAngelis RA, Reis ES, Ricklin D, Lambris JD. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology 2012;217:1097-105. [PMID: 22964235 DOI: 10.1016/j.imbio.2012.07.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
158 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
159 Han SR, Cho MH, Moon JS, Ha IS, Cheong HI, Kang HG. Life-Threatening Extrarenal Manifestations in an Infant with Atypical Hemolytic Uremic Syndrome Caused by a Complement 3-Gene Mutation. Kidney Blood Press Res 2019;44:1300-5. [PMID: 31522186 DOI: 10.1159/000502289] [Reference Citation Analysis]
160 Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. Case Rep Nephrol 2019;2019:9264824. [PMID: 31360562 DOI: 10.1155/2019/9264824] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Mittal N, Hartemayer R, Jandeska S, Giordano L. Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. J Pediatr Hematol Oncol 2019;41:e63-7. [PMID: 29702545 DOI: 10.1097/MPH.0000000000001180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Wu X, Szarzanowicz A, Garba A, Schaefer B, Waz WR. Blockade of the Terminal Complement Cascade Using Ravulizumab in a Pediatric Patient With Anti-complement Factor H Autoantibody-Associated aHUS: A Case Report and Literature Review. Cureus 2021;13:e19476. [PMID: 34912617 DOI: 10.7759/cureus.19476] [Reference Citation Analysis]
163 Pérez-Calatayud ÁA, Briones-Garduño JC, Álvarez-Goris Mdel P, Sánchez Zamora R, Torres Aguilar AA, Mendoza-Mórales RE. [Atipical uremic hemolityc syndrome in pregnancy]. Cir Cir 2016;84:344-9. [PMID: 27004941 DOI: 10.1016/j.circir.2016.02.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
165 Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Killen P, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol 2017;28:3066-75. [PMID: 28526779 DOI: 10.1681/ASN.2017010031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
166 Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-gvili A. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Renal Failure 2014;36:1119-21. [DOI: 10.3109/0886022x.2014.917574] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
167 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Biologie 2015;63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
168 Michael M, Turner N, Elenberg E, Shaffer LG, Teruya J, Arar M, Hui SK, Smith RJ, Moake J. Deficiency of complement factor H-related proteins and autoantibody-positive hemolytic uremic syndrome in an infant with combined partial deficiencies and autoantibodies to complement factor H and ADAMTS13. Clin Kidney J 2018;11:791-6. [PMID: 30524124 DOI: 10.1093/ckj/sfy010] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
169 Ávila A, Vizcaíno B, Molina P, Gavela E, Perez-Ebri M, Pallardó L. Remission of aHUS neurological damage with eculizumab. Clin Kidney J 2015;8:232-6. [PMID: 25815183 DOI: 10.1093/ckj/sfu144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
170 Vaught AJ, Braunstein E, Chaturvedi S, Blakemore K, Brodsky RA. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med 2020;:1-9. [PMID: 32338085 DOI: 10.1080/14767058.2020.1755650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
171 Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab 2021;10:225-30. [PMID: 34765894 DOI: 10.1097/XCE.0000000000000247] [Reference Citation Analysis]
172 Sartain SE, Turner NA, Moake JL. TNF Regulates Essential Alternative Complement Pathway Components and Impairs Activation of Protein C in Human Glomerular Endothelial Cells. J I 2016;196:832-45. [DOI: 10.4049/jimmunol.1500960] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
173 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
174 Ojeda-Uribe M, Merieau S, Guillon M, Aujoulat O, Hinschberger O, Eisenmann JC, Kenizou D, Debliquis A, Veyradier A, Chantrel F. Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate. J Oncol Pharm Pract 2016;22:361-70. [PMID: 25591869 DOI: 10.1177/1078155214568580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
175 Cataland SR, Wu HM. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies. European Journal of Internal Medicine 2013;24:486-91. [DOI: 10.1016/j.ejim.2013.05.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
176 Besouw MT, Vande Walle JG, Ilias MI, Raes AM, Prytula AA, Claeys L, Dehoorne JL. Pediatric lupus nephritis presenting with terminal renal failure. Acta Clin Belg 2016;71:455-7. [PMID: 27169353 DOI: 10.1080/17843286.2016.1159383] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
177 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
178 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. Clin Exp Nephrol 2014;18:4-9. [DOI: 10.1007/s10157-013-0911-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
179 Vaughn JL, Moore JM, Cataland SR. Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Rep Hematol 2015;2015:327980. [PMID: 26557394 DOI: 10.1155/2015/327980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:783-9. [DOI: 10.1007/s00467-014-3003-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
181 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
182 Kok VC, Wu SC, Lee CK. Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer. Breast Cancer (Auckl) 2014;8:57-9. [PMID: 24701120 DOI: 10.4137/BCBCR.S14920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
183 Frémeaux-Bacchi V. [Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient]. Biol Aujourdhui 2013;207:231-40. [PMID: 24594571 DOI: 10.1051/jbio/2013027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
184 Ahmed Ali EM, Abbakar NM, Abdel Raheem MB, Ellidir RA. Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State. Sudan J Paediatr 2017;17:42-8. [PMID: 29545664 DOI: 10.24911/SJP.2017.2.5] [Reference Citation Analysis]
185 Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, Fremeaux-Bacchi V, Le Meur Y. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014;63:119-23. [PMID: 24210589 DOI: 10.1053/j.ajkd.2013.08.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
186 Kichloo A, Chugh SS, Gupta S, Pandav J, Chander P. Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy. J Investig Med High Impact Case Rep 2019;7:2324709619842905. [PMID: 31010328 DOI: 10.1177/2324709619842905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Romero S, Sempere A, Gómez-seguí I, Román E, Moret A, Jannone R, Moreno I, Mendizábal S, Espí J, Peris A, Carbonell R, Cervera J, Pemán J, Bonanad S, de la Rubia J, Jarque I. Guía práctica de tratamiento urgente de la microangiopatía trombótica. Medicina Clínica 2018;151:123.e1-9. [DOI: 10.1016/j.medcli.2018.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Caetano R, Rodrigues PHA, Corrêa MCV, Villardi P, Osorio-de-Castro CGS. The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health. Rev Saude Publica 2020;54:22. [PMID: 32130309 DOI: 10.11606/s1518-8787.2020054001693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Clark WF, Patriquin C, Licht C, Huang SH, Rock G. Simple diagnosis and treatment algorithm for adult thrombotic microangiopathy. Transfus Apher Sci 2017;56:50-1. [PMID: 28139433 DOI: 10.1016/j.transci.2016.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
191 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
192 Brunelli SM, Claxton A, Mehta S, Anum EA. Consequences of hemolytic uremic syndrome among hemodialysis patients. J Nephrol 2015;28:361-7. [PMID: 25491936 DOI: 10.1007/s40620-014-0149-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
193 Webb TN, Griffiths H, Miyashita Y, Bhatt R, Jaffe R, Moritz M, Hofer J, Swiatecka-Urban A. Atypical Hemolytic Uremic Syndrome and Chronic Ulcerative Colitis Treated with Eculizumab. Int J Med Pharm Case Reports 2015;4:105-12. [PMID: 27135055 DOI: 10.9734/IJMPCR/2015/18771] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
194 Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 2021;14:e239091. [PMID: 33637496 DOI: 10.1136/bcr-2020-239091] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
195 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
196 Mittal K, Cheema R, Mahajan V, Kumar P, Kaur R, Sood T, Kaur P. Challenges in management of atypical hemolytic uremic syndrome: Bottle neck in resource limited settings. Transfus Clin Biol 2021:S1246-7820(21)00091-4. [PMID: 34284115 DOI: 10.1016/j.tracli.2021.07.002] [Reference Citation Analysis]
197 Kim S, Park E, Min SI, Yi NJ, Ha J, Ha IS, Cheong HI, Kang HG. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. J Korean Med Sci 2018;33:e4. [PMID: 29215813 DOI: 10.3346/jkms.2018.33.e4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
198 Agudo I, Souto-Moura T, Azevedo L, Cavaco R, Germano N, Bento L. Atypical hemolytic uremic syndrome in intensive care: Case report in an adult. Med Intensiva 2016;40:188-90. [PMID: 26596222 DOI: 10.1016/j.medin.2015.09.007] [Reference Citation Analysis]
199 Bjerre A, Bergseth G, Ludviksen JK, Stokke A, Bosnes V, Karpman D, Mollnes TE. Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Rep Nephrol 2018;2018:3810249. [PMID: 30662780 DOI: 10.1155/2018/3810249] [Reference Citation Analysis]
200 Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report. Transplant Proc. 2012;44:3037-3040. [PMID: 23195022 DOI: 10.1016/j.transproceed.2012.07.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
201 Abazi-Emini N, Sahpazova E, Putnik J, Tasic V. Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome: A Case Report. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2021;42:109-15. [PMID: 34699711 DOI: 10.2478/prilozi-2021-0029] [Reference Citation Analysis]
202 Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020;12:295-305. [PMID: 32210633 DOI: 10.2147/clep.s245642] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
203 Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud 2019;7:35-40. [PMID: 31312592 DOI: 10.5414/CNCS109511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Nayer A, Asif A. Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther. 2016;23:e151-e158. [PMID: 24681522 DOI: 10.1097/mjt.0b013e31829b59dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
205 Smirnova TV, Sheludchenko VM, Kozlovskaya NL, Kazaryan EE, Andzhelova DV, Sherstneva LV, Velieva IA, Kuchieva AM, Akaeva MI. [Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)]. Vestn Oftalmol 2018;134:215-26. [PMID: 30499520 DOI: 10.17116/oftalma2018134051215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Onclinx C, Dogne S, Jadin L, Andris F, Grandfils C, Jouret F, Mullier F, Flamion B. Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy. Haematologica 2015;100:1023-30. [PMID: 25934767 DOI: 10.3324/haematol.2015.123828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
207 Fan X, Yoshida Y, Honda S, Matsumoto M, Sawada Y, Hattori M, Hisanaga S, Hiwa R, Nakamura F, Tomomori M, Miyagawa S, Fujimaru R, Yamada H, Sawai T, Ikeda Y, Iwata N, Uemura O, Matsukuma E, Aizawa Y, Harada H, Wada H, Ishikawa E, Ashida A, Nangaku M, Miyata T, Fujimura Y. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Molecular Immunology 2013;54:238-46. [DOI: 10.1016/j.molimm.2012.12.006] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
208 Makatsariya AD, Slukhanchuk EV, Bitsadze VO, Khizroeva JKH, Tretyakova MV, Tsibizova VI, Elalamy I, Gris JC, Grandone E, Makatsariya NA, Mashkova T. Thrombotic microangiopathy, DIC-syndrome and COVID-19: link with pregnancy prothrombotic state. J Matern Fetal Neonatal Med 2020;:1-9. [PMID: 32627622 DOI: 10.1080/14767058.2020.1786811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
209 Chidambaram AC, Krishnamurthy S, Deepthi B, Karunakar P, Maulik K, Peela SCM, Sistla S, Jinkala SR. Severe acute kidney injury in a 3-year-old boy with fever and pleural effusion: Answers. Pediatr Nephrol 2020;35:2279-83. [PMID: 32468115 DOI: 10.1007/s00467-020-04591-7] [Reference Citation Analysis]
210 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
211 Kalambay J, Zaman R, Zaman M. Atypical Hemolytic Uremic Syndrome Presenting as Pre-eclampsia in a 24-year-old Woman with Chronic Kidney Disease: Pathogenesis and Genetics. Cureus 2018;10:e3358. [PMID: 30510868 DOI: 10.7759/cureus.3358] [Reference Citation Analysis]
212 van Werkhoven MB, Damman J, Daha MR, Krikke C, van Goor H, van Son WJ, Hillebrands J, van Dijk MC, Seelen MA. Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney. Molecular Immunology 2013;53:237-45. [DOI: 10.1016/j.molimm.2012.08.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
213 Reid VL, Mullan A, Erwig LP. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange. BMJ Case Rep 2013;2013:bcr2013200980. [PMID: 24005975 DOI: 10.1136/bcr-2013-200980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
214 Franco-Jarava C, Álvarez de la Campa E, Solanich X, Morandeira-Rego F, Mas-Bosch V, García-Prat M, de la Cruz X, Martín-Nalda A, Soler-Palacín P, Hernández-González M, Colobran R. Early Versus Late Diagnosis of Complement Factor I Deficiency: Clinical Consequences Illustrated in Two Families with Novel Homozygous CFI Mutations. J Clin Immunol 2017;37:781-9. [PMID: 28942469 DOI: 10.1007/s10875-017-0447-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
215 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
216 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
217 Pepper RJ, Trompeter RS. The causes and consequences of paediatric kidney disease on adult nephrology care. Pediatr Nephrol 2021. [PMID: 34389906 DOI: 10.1007/s00467-021-05182-w] [Reference Citation Analysis]
218 Turner N, Sartain S, Moake J. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes.Hematol Oncol Clin North Am. 2015;29:509-524. [PMID: 26043389 DOI: 10.1016/j.hoc.2015.01.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
219 Hyvärinen S, Uchida K, Varjosalo M, Jokela R, Jokiranta TS. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome. J Biol Chem 2014;289:4295-306. [PMID: 24344133 DOI: 10.1074/jbc.M113.527416] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
220 Fremeaux-Bacchi V. Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J 2012;5:4-6. [PMID: 26069738 DOI: 10.1093/ckj/sfr177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
221 Veríssimo R, Mateus C, Laranjinha I, Manso RT, Dickson J, Gonçalves M, Gaspar MA, Machado D. Thrombotic microangiopathy triggered by podocytopathy. Clin Nephrol Case Stud 2021;9:110-6. [PMID: 34646728 DOI: 10.5414/CNCS110534] [Reference Citation Analysis]
222 Prohászka Z, Varga L, Füst G. The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. Br J Haematol 2012;158:424-5. [DOI: 10.1111/j.1365-2141.2012.09168.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
223 De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM. Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 2015;28:641-5. [DOI: 10.1007/s40620-015-0173-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
224 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
225 Bermea RS, Sharma N, Cohen K, Liarski VM. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol 2016;22:320-3. [PMID: 27556240 DOI: 10.1097/RHU.0000000000000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
226 Keating GM. Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs Ther Perspect 2014;30:166-72. [DOI: 10.1007/s40267-014-0120-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
227 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Ažukaitis K, Loirat C, Malina M, Adomaitienė I, Jankauskienė A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1273-7. [PMID: 24352218 DOI: 10.1007/s00467-013-2713-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
229 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:536-43. [PMID: 27422619 DOI: 10.1007/s10157-016-1276-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
230 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 216] [Article Influence: 33.6] [Reference Citation Analysis]
231 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
232 Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013;8:407-15. [PMID: 23243267 DOI: 10.2215/CJN.01260212] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
233 Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens 2021;10:727. [PMID: 34207609 DOI: 10.3390/pathogens10060727] [Reference Citation Analysis]
234 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
235 Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 2014;36:381-97. [PMID: 24715030 DOI: 10.1007/s00281-014-0423-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
236 Hunt EA, Jain NG, Somers MJ. Apheresis therapy in children: An overview of key technical aspects and a review of experience in pediatric renal disease: Apheresis Therapy in Children. J Clin Apheresis 2013;28:36-47. [DOI: 10.1002/jca.21260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
237 Li QL, Song WQ, Peng XX, Liu XR, He LJ, Fu LB. Clinical characteristics of hemolytic uremic syndrome secondary to cobalamin C disorder in Chinese children. World J Pediatr 2015;11:276-80. [PMID: 26253414 DOI: 10.1007/s12519-015-0032-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
238 Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Sengul Samanci N, Ayer M, Ergen A, Ozturk S. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report. Transfus Apher Sci 2015;52:314-6. [PMID: 25634788 DOI: 10.1016/j.transci.2015.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
240 Das A, Dean A, Clay T. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. BMJ Case Rep 2019;12:e228363. [PMID: 30962211 DOI: 10.1136/bcr-2018-228363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep 2015;4:36-8. [PMID: 26052501 DOI: 10.1016/j.lrr.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
242 Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, Paracchini V, Tel F, Possenti I, Belingheri M, Civitillo CF, Sardini S, Ceruti R, Baldioli C, Tommasi P, Parola L, Russo F, Tedeschi S. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr 2016;175:465-73. [PMID: 26498648 DOI: 10.1007/s00431-015-2642-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
243 Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014;29:2415-9. [PMID: 25149852 DOI: 10.1007/s00467-014-2933-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
244 Cody EM, Dixon BP. Hemolytic Uremic Syndrome. Pediatric Clinics of North America 2019;66:235-46. [DOI: 10.1016/j.pcl.2018.09.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
245 Galán-Sánchez F, Guerrero-Lozano I, Rubio-Quiñones F, Rodríguez-Iglesias M. Haemolytic uraemic syndrome associated with bloody diarrhoea caused by Streptococcus dysgalactiae. Enferm Infecc Microbiol Clin 2013;31:60-1. [PMID: 22955002 DOI: 10.1016/j.eimc.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
246 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
247 Chen P, Zhu L, Yu F, Han SS, Meng SJ, Guo WY, Zhang H, Song Y. Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: A case report. Medicine (Baltimore) 2017;96:e7144. [PMID: 28614243 DOI: 10.1097/MD.0000000000007144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
248 Robertson JJ, Brem E, Koyfman A. The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management. The Journal of Emergency Medicine 2017;53:202-11. [DOI: 10.1016/j.jemermed.2017.02.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Ardissino G, Wally Ossola M, Maria Baffero G, Rigotti A, Cugno M. Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy. Obstetrics & Gynecology 2013;122:487-9. [DOI: 10.1097/aog.0b013e31828e2612] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
250 Nichols MM, Crane GM. Educational Case: Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies and Potential Role of the Spleen. Acad Pathol 2021;8:23742895211001312. [PMID: 33855171 DOI: 10.1177/23742895211001312] [Reference Citation Analysis]
251 Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 2016;95:e4104. [PMID: 27399110 DOI: 10.1097/MD.0000000000004104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Duquenne L, Balbeur S, Everard E, Reding R, Eeckhoudt S, Brichard B, Godefroid N, Derycke E, Komuta M, Scheers I, Smets F, Sokal E, Stéphenne X. vWFpp/ADAMTS13 ratio is a useful marker of postliver transplantation thrombotic microangiopathy: A pediatric case report. Clin Case Rep 2020;8:41-6. [PMID: 31998483 DOI: 10.1002/ccr3.2495] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Caroti L, Di Maria L, Carta P, Moscarelli L, Cirami C, Minetti EE. Posttransplant outcome of atypical haemolytic uraemic syndrome in a patient with thrombomodulin mutation: a case without recurrence. Clin Kidney J 2015;8:329-31. [PMID: 26034596 DOI: 10.1093/ckj/sfv025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
254 Clark WF, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, Kelton JG, Li L, Foley SR; members of Canadian Apheresis Group. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol 2015;170:208-17. [PMID: 25855259 DOI: 10.1111/bjh.13408] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
255 Yun EJ, Lee SH, Kim S, Kim SH, Kim KH. Global profiling of metabolic response of Caenorhabditis elegans against Escherichia coli O157:H7. Process Biochemistry 2017;53:36-43. [DOI: 10.1016/j.procbio.2016.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
256 Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64:633-737. [PMID: 24656451 DOI: 10.1053/j.ajkd.2014.01.434] [Cited by in Crossref: 132] [Cited by in F6Publishing: 106] [Article Influence: 16.5] [Reference Citation Analysis]
257 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
258 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58:549-555. [PMID: 27460397 DOI: 10.1111/ped.13044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
259 Chung C. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab. Ann Pharmacother 2021;55:330-43. [PMID: 32715723 DOI: 10.1177/1060028020941852] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Dierickx D, Beke E, Devos T, Delannoy A. The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America 2012;96:583-619. [DOI: 10.1016/j.mcna.2012.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
261 Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78. [PMID: 27452363 DOI: 10.1038/nrneph.2016.99] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
262 Lee YC, Wang JS, Shiang JC, Tsai MK, Deng KT, Chang MY, Wang HH, Ho LC, Chen YT, Hung SY. Haemolytic uremic syndrome following fire ant bites. BMC Nephrol 2014;15:5. [PMID: 24400942 DOI: 10.1186/1471-2369-15-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
263 Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney International 2016;90:974-84. [DOI: 10.1016/j.kint.2016.06.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
264 Korotchaeva J, Chebotareva N, Andreeva E, Sorokin Y, McDonnell V, Stolyarevich E, Moiseev S. Thrombotic Microangiopathy Triggered by COVID-19: Case Reports. Nephron 2021;:1-6. [PMID: 34808629 DOI: 10.1159/000520144] [Reference Citation Analysis]
265 Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep 2016;4:773-6. [PMID: 27525082 DOI: 10.1002/ccr3.628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
266 Alba-Domínguez M, López-Lera A, Garrido S, Nozal P, González-Granado I, Melero J, Soler-Palacín P, Cámara C, López-Trascasa M. Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis 2012;7:42. [PMID: 22710145 DOI: 10.1186/1750-1172-7-42] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
267 Jiang H, Fan MN, Yang M, Lu C, Zhang M, Liu XH, Ma L. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome. Int J Environ Res Public Health 2016;13:E1209. [PMID: 27929404 DOI: 10.3390/ijerph13121209] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
268 Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014;25:55-64. [PMID: 24029428 DOI: 10.1681/ASN.2013050453] [Cited by in Crossref: 144] [Cited by in F6Publishing: 65] [Article Influence: 16.0] [Reference Citation Analysis]
269 Cataland SR, Wu HM. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Reviews 2014;28:67-74. [DOI: 10.1016/j.blre.2014.01.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
270 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
271 Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, Hari P, Sharma A, Bagga A. Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. Clin Kidney J 2018;11:198-203. [PMID: 29644059 DOI: 10.1093/ckj/sfx078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
272 Al-Shyoukh A, Younis M, Abughanimeh O, Tahboub M, Hamarshi MS. An Unusual Case of Diffuse Alveolar Hemorrhage as a Clinical Manifestation of Atypical Hemolytic Uremic Syndrome: A Case Report. Cureus 2019;11:e5059. [PMID: 31516771 DOI: 10.7759/cureus.5059] [Reference Citation Analysis]
273 Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology 2012;2012:617-25. [DOI: 10.1182/asheducation.v2012.1.617.3798924] [Cited by in Crossref: 66] [Article Influence: 6.6] [Reference Citation Analysis]
274 Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin 2020;36:333-56. [PMID: 32172817 DOI: 10.1016/j.ccc.2019.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
275 Pouw RB, Vredevoogd DW, Kuijpers TW, Wouters D. Of mice and men: The factor H protein family and complement regulation. Mol Immunol 2015;67:12-20. [PMID: 25824240 DOI: 10.1016/j.molimm.2015.03.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
276 Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D'Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014;25:1408-14. [PMID: 24511134 DOI: 10.1681/ASN.2013080886] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
277 Fagiuoli S, Daina E, D'Antiga L, Colledan M, Remuzzi G. Monogenic diseases that can be cured by liver transplantation. J Hepatol. 2013;59:595-612. [PMID: 23578885 DOI: 10.1016/j.jhep.2013.04.004] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 9.0] [Reference Citation Analysis]
278 Vanaja SK, Jandhyala DM, Mallick EM, Leong JM, Balasubramanian S. Enterohemorrhagic and other Shigatoxin-producing Escherichia coli. Escherichia coli. Elsevier; 2013. pp. 121-82. [DOI: 10.1016/b978-0-12-397048-0.00005-x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
279 Singh K, Nadeem AJ, Doratotaj B. A rare case of thrombotic microangiopathy triggered by acute pancreatitis. BMJ Case Rep 2017;2017:bcr-2016-218581. [PMID: 28512098 DOI: 10.1136/bcr-2016-218581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
280 Ferreira E, Oliveira N, Marques M, Pinto H, Santos A, Carreira A, Campos M. Subcapsular liver hematoma as a complication of an atypical hemolytic uremic syndrome. Nefrología 2015;35:337-9. [DOI: 10.1016/j.nefro.2015.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
281 Wu H, Su S, Li L, Zhang L. Atypical hemolytic uremic syndrome and acute tubular necrosis induced by complement factor B gene (CFB) mutation: A case report. Medicine (Baltimore) 2021;100:e25069. [PMID: 33725982 DOI: 10.1097/MD.0000000000025069] [Reference Citation Analysis]
282 Mannucci P, Cugno M. The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research 2015;136:851-4. [DOI: 10.1016/j.thromres.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
283 Modde F, Agustian PA, Wittig J, Dämmrich ME, Forstmeier V, Vester U, Ahlenstiel T, Froede K, Budde U, Wingen A, Schwarz A, Lovric S, Kielstein JT, Bergmann C, Bachmann N, Nagel M, Kreipe HH, Bröcker V, Bockmeyer CL, Becker JU. Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). Virchows Arch 2013;462:455-64. [DOI: 10.1007/s00428-013-1386-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
284 Casiraghi F, Ordonez PYR, Azzollini N, Todeschini M, Rottoli D, Donadelli R, Gramignoli R, Benigni A, Noris M, Remuzzi G. Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. Stem Cell Res Ther 2021;12:332. [PMID: 34112227 DOI: 10.1186/s13287-021-02386-7] [Reference Citation Analysis]
285 Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J Med Case Rep 2014;8:307. [PMID: 25219386 DOI: 10.1186/1752-1947-8-307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
286 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
287 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
288 Alsaied T, Goldstein SL, Kaddourah A, Poynter SE. Thrombocytopenia-associated multi-organ failure caused by diabetic ketoacidosis. Pediatr Int 2016;58:232-4. [PMID: 26712331 DOI: 10.1111/ped.12780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
289 González DP, Iglicki M, Svetitsky S, Bar-On Y, Habot-Wilner Z, Zur D. Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome - a case report. BMC Ophthalmol 2021;21:65. [PMID: 33516177 DOI: 10.1186/s12886-021-01820-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Hyvärinen S, Jokiranta TS. Minor Role of Plasminogen in Complement Activation on Cell Surfaces. PLoS One 2015;10:e0143707. [PMID: 26637181 DOI: 10.1371/journal.pone.0143707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
291 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
292 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
293 Hassan S, Westwood J, Ellis D, Laing C, Mc Guckin S, Benjamin S, Scully M. The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. Br J Haematol 2015;171:830-5. [DOI: 10.1111/bjh.13654] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
294 Cataland SR, Wu HM. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014;123:2478-84. [PMID: 24599547 DOI: 10.1182/blood-2013-11-516237] [Cited by in Crossref: 86] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
295 Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78. [PMID: 24817340 DOI: 10.1007/s00467-014-2817-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
296 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
297 Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, Mudge D, Carroll R, Kausman J, Hughes P, Barbour T, Durkan A, Mount P, Lee D, Larkins N, Ranganathan D, Lim WH. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology (Carlton) 2020;25:683-90. [PMID: 32378251 DOI: 10.1111/nep.13722] [Reference Citation Analysis]
298 Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013;28:155-8. [PMID: 22956028 DOI: 10.1007/s00467-012-2296-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
299 Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85:1151-1160. [PMID: 24088957 DOI: 10.1038/ki.2013.373] [Cited by in Crossref: 117] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
300 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
301 Lee J. Early infantile onset of atypical hemolytic-uremic syndrome is caused by recessive mutations in DGKE: HotSpots. Clin Genet 2013;84:342-3. [DOI: 10.1111/cge.12240] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
302 Robitaille P, Clermont MJ, Mérouani A, Phan V, Lapeyraque AL. Hemolytic uremic syndrome: late renal injury and changing incidence-a single centre experience in Canada. Scientifica (Cairo) 2012;2012:341860. [PMID: 24278685 DOI: 10.6064/2012/341860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
303 Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:265-72. [DOI: 10.1007/s10157-015-1142-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
304 Nikolajeva O, Worth A, Hague R, Martinez-Alier N, Smart J, Adams S, Davies EG, Gaspar HB. Adenosine deaminase deficient severe combined immunodeficiency presenting as atypical haemolytic uraemic syndrome. J Clin Immunol 2015;35:366-72. [PMID: 25875700 DOI: 10.1007/s10875-015-0158-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
305 Salem G, Flynn JM, Cataland SR. Profound neurological injury in a patient with atypical hemolytic uremic syndrome. Ann Hematol 2013;92:557-8. [DOI: 10.1007/s00277-012-1615-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
306 Fidan K, Göknar N, Gülhan B, Melek E, Yıldırım ZY, Baskın E, Hayran M, Gülleroglu K, Özçakar ZB, Ozaltin F, Soylemezoglu O. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2018;33:1395-403. [PMID: 29610995 DOI: 10.1007/s00467-018-3933-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
307 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
308 Thorenz A, Derlin K, Schröder C, Dressler L, Vijayan V, Pradhan P, Immenschuh S, Jörns A, Echtermeyer F, Herzog C, Chen R, Rong S, Bräsen JH, van Kooten C, Kirsch T, Klemann C, Meier M, Klos A, Haller H, Hensen B, Gueler F. Enhanced activation of interleukin-10, heme oxygenase-1, and AKT in C5aR2-deficient mice is associated with protection from ischemia reperfusion injury-induced inflammation and fibrosis. Kidney Int 2018;94:741-55. [PMID: 29935951 DOI: 10.1016/j.kint.2018.04.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
309 Tseng MH, Tsai JD, Tsai IJ, Huang SM, Huang JL, Fan WL, Lee HJ, Wu TW, Lin SH. Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan. Clin Chim Acta 2019;494:143-50. [PMID: 30905589 DOI: 10.1016/j.cca.2019.03.1623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Sabry W, Elemary M, Burnouf T, Seghatchian J, Goubran H. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). Transfus Apher Sci 2020;59:102717. [PMID: 31902683 DOI: 10.1016/j.transci.2019.102717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
311 Jlajla H, Dehman F, Jallouli M, Khedher R, Ayadi I, Zerzeri Y, Laadhar L, Sfar I, Mahfoudh A, Gorgi Y, Cheour E, Zouaghi K, Gargah T, Kallel Sellami M. Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients. Nephrology (Carlton) 2019;24:357-64. [PMID: 29292855 DOI: 10.1111/nep.13217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
312 Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet 2018;30:400-9. [PMID: 30930551 DOI: 10.1007/s11825-018-0216-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
313 Ipe TS, Lim J, Reyes MA, Ero M, Leveque C, Lewis B, Kain J. An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome. J Clin Apher 2017;32:584-8. [PMID: 28455885 DOI: 10.1002/jca.21549] [Reference Citation Analysis]
314 Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 2013;190:3831-8. [PMID: 23564577 DOI: 10.4049/jimmunol.1203487] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 32.0] [Reference Citation Analysis]
315 Koenig JC, Rutsch F, Bockmeyer C, Baumgartner M, Beck BB, Kranz B, Konrad M. Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatr Nephrol 2015;30:1203-6. [PMID: 25894566 DOI: 10.1007/s00467-015-3110-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
316 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
317 Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia 2016;36:72-5. [PMID: 26541438 DOI: 10.1016/j.nefro.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
318 Nagar VS, Chaterjee R, Sood A, Sajjan B, Kaushik A, Vyahalkar SV. Complements Spurned: Our Experience with Atypical Hemolytic Uremic Syndrome. Indian J Crit Care Med 2017;21:102-4. [PMID: 28250608 DOI: 10.4103/ijccm.IJCCM_341_16] [Reference Citation Analysis]
319 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
320 Park HJ, Atkinson JP. Autoimmunity: homeostasis of innate immunity gone awry. J Clin Immunol 2012;32:1148-52. [PMID: 23054347 DOI: 10.1007/s10875-012-9815-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
321 Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, Grangé S, Burtey S, Coindre JP, Wynckel A, Hamidou MA, Kanouni T, Azoulay E, Hié M, Chauveau D, Veyradier A, Rondeau E, Coppo P; French Reference Centre for Thrombotic Microangiopathies. Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. Eur J Intern Med 2021:S0953-6205(21)00199-0. [PMID: 34175183 DOI: 10.1016/j.ejim.2021.05.040] [Reference Citation Analysis]
322 Chen FY, Chen CH, Lin CC. Hypertensive Crisis and Refractory Hypertension Caused by Atypical Hemolytic Uremic Syndrome and Effect of Eculizumab. Acta Cardiol Sin 2018;34:446-9. [PMID: 30271097 DOI: 10.6515/ACS.201809_34(5).20180326D] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
323 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]